rofecoxib has been researched along with Osteoarthritis of Knee in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 9.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 6.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "5), with symptomatic osteoarthritis of hip or knee were included in an open label study with rofecoxib." | 5.11 | Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib. ( Bellamy, N; Bischoff-Ferrari, HA; Good, M; Theiler, R, 2004) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 5.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| " We report two cases of acute psychotic syndromes with visual (Case 1 + 2) and auditory (Case 1) hallucinations under rofecoxib, a cyclooxygenase-2-inhibitor." | 3.74 | [Rofecoxib-induced psychosis]. ( Connemann, BJ; Kassubek, J; Sabolek, M; Sperfeld, AD; Unrath, A, 2007) |
| " Rofecoxib at a dosage of 12." | 2.72 | Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. ( Geba, GP; Messner, RP; Najarian, DK; Petruschke, RA; Polis, AB; Storms, WW; Tershakovec, AM; Weaver, AL, 2006) |
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 2.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| " The main safety measure was adverse events during the 6 weeks of treatment." | 2.71 | Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. ( Baraf, HS; Cohen, SB; Dixon, ME; Geba, GP; Green, JA; Greenwald, MW; Kivitz, AJ; Matsumoto, AK; Moidel, RA; Najarian, DK; Petruschke, RA; Polis, AB, 2004) |
| "Rofecoxib treatment, with its faster onset of OA efficacy and lower rates of related discontinuations, might provide efficacy advantages in the treatment of OA pain." | 2.71 | Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. ( Battisti, WP; Geba, GP; Katz, NP; Kivitz, AJ; Matsumoto, AK; Polis, AB; Weaver, AL, 2004) |
| "To compare the efficacy, safety, and tolerability of AZD3582 with that of rofecoxib, naproxen, and placebo in patients with osteoarthritis (OA) of the knee, and to define the dosage of AZD3582 (125 mg, 375 mg, and 750 mg twice a day) that is noninferior in efficacy to rofecoxib." | 2.71 | Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. ( Hee, A; Kivitz, AJ; Lipetz, RS; Sanders, N; Schnitzer, TJ, 2005) |
| "Rofecoxib and naproxen were generally well tolerated." | 2.70 | Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. ( Amante, C; Chen, SL; Choon, D; Chow, CT; De Tora, L; Genti, G; Laurenzi, M; Lu, HS; Moan, A; Myllykangas-Luosujärvi, R; Pasero, G; Rodgers, DB; Sarembock, B; Vrijens, F; Zerbini, CA, 2002) |
| "Both rofecoxib doses were generally well tolerated." | 2.69 | Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. ( Bolognese, J; Ehrich, EW; Gertz, BJ; Levy, R; McIlwain, H; Morrison, B; Schnitzer, TJ; Seidenberg, B; Weisman, M; Wolfe, F; Zeng, Q, 1999) |
| "Rofecoxib was well tolerated and provided efficacy that was clinically comparable, according to predefined statistical criteria, to that of 150 mg of diclofenac per day in this 1-year study." | 2.69 | Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 ( Bolognese, J; Caldwell, JR; Cannon, GW; Daniels, B; Ehrich, E; Holt, P; McLean, B; Mukhopadhyay, S; Seidenberg, B, 2000) |
| " Following dosing of CFA-injected rats with rofecoxib (Vioxx) or paracetamol, there was a significant decrease in the number of ipsilateral CGRP-IR small and medium DRG neurones in rofecoxib- but not paracetamol-treated rats." | 1.34 | Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol. ( Bountra, C; Chessell, IP; Day, NC; Staton, PC; Wilson, AW, 2007) |
| "Rofecoxib was recalled in September 2004 when studies identified increased cardiovascular risk compared with placebo among patients taking rofecoxib." | 1.33 | The patient's perspective on the recall of Vioxx. ( Hawker, GA; Katz, JN; Solomon, DH, 2006) |
| " Adverse events were closely monitored." | 1.32 | Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. ( Bannwarth, B; Dougados, M; Euller-Ziegler, L; Ravaud, P; Rolland, D; Trèves, R, 2003) |
| "Rofecoxib is a highly selective inhibitor of cyclooxygenase-2 used in symptomatic treatment of inflammation and pain in patients with osteoarthritis of the hip or knee." | 1.31 | Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. ( Bischoff, HA; Good, M; Theiler, R; Uebelhart, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 26 (92.86) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, T | 1 |
| Lu, N | 1 |
| Felson, DT | 1 |
| Choi, HK | 1 |
| Dalal, DS | 1 |
| Zhang, Y | 1 |
| Dubreuil, M | 1 |
| Schnitzer, TJ | 6 |
| Tesser, JR | 1 |
| Cooper, KM | 1 |
| Altman, RD | 1 |
| Myllykangas-Luosujärvi, R | 1 |
| Lu, HS | 1 |
| Chen, SL | 1 |
| Choon, D | 1 |
| Amante, C | 1 |
| Chow, CT | 1 |
| Pasero, G | 1 |
| Genti, G | 1 |
| Sarembock, B | 1 |
| Zerbini, CA | 1 |
| Vrijens, F | 1 |
| Moan, A | 1 |
| Rodgers, DB | 1 |
| De Tora, L | 1 |
| Laurenzi, M | 1 |
| Bannwarth, B | 1 |
| Trèves, R | 1 |
| Euller-Ziegler, L | 1 |
| Rolland, D | 1 |
| Ravaud, P | 1 |
| Dougados, M | 1 |
| Theiler, R | 2 |
| Bischoff, HA | 1 |
| Good, M | 2 |
| Uebelhart, D | 1 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Kivitz, AJ | 3 |
| Greenwald, MW | 1 |
| Cohen, SB | 1 |
| Polis, AB | 6 |
| Najarian, DK | 2 |
| Dixon, ME | 2 |
| Moidel, RA | 1 |
| Green, JA | 1 |
| Baraf, HS | 1 |
| Petruschke, RA | 3 |
| Matsumoto, AK | 2 |
| Geba, GP | 5 |
| Bischoff-Ferrari, HA | 1 |
| Bellamy, N | 1 |
| Battisti, WP | 1 |
| Katz, NP | 1 |
| Weaver, AL | 5 |
| Khan, FY | 1 |
| Hassan, IF | 1 |
| Allity, MH | 1 |
| Khan, SM | 1 |
| Karamanlioğlu, B | 1 |
| Alagöl, A | 1 |
| Turan, FN | 1 |
| Lipetz, RS | 1 |
| Sanders, N | 1 |
| Hee, A | 1 |
| Shen, H | 1 |
| Sprott, H | 2 |
| Aeschlimann, A | 1 |
| Gay, RE | 1 |
| Michel, BA | 1 |
| Gay, S | 1 |
| Messner, RP | 1 |
| Storms, WW | 1 |
| Tershakovec, AM | 2 |
| Staton, PC | 1 |
| Wilson, AW | 1 |
| Bountra, C | 1 |
| Chessell, IP | 1 |
| Day, NC | 1 |
| Hawker, GA | 1 |
| Katz, JN | 1 |
| Solomon, DH | 1 |
| Bove, SE | 1 |
| Laemont, KD | 1 |
| Brooker, RM | 1 |
| Osborn, MN | 1 |
| Sanchez, BM | 1 |
| Guzman, RE | 1 |
| Hook, KE | 1 |
| Juneau, PL | 1 |
| Connor, JR | 1 |
| Kilgore, KS | 1 |
| Moskowitz, RW | 1 |
| Sunshine, A | 1 |
| Hooper, M | 1 |
| Olson, NZ | 1 |
| Cawkwell, GD | 1 |
| Smugar, SS | 1 |
| Rubin, BR | 1 |
| Sabolek, M | 1 |
| Unrath, A | 1 |
| Sperfeld, AD | 1 |
| Connemann, BJ | 1 |
| Kassubek, J | 1 |
| Ehrich, EW | 1 |
| McIlwain, H | 1 |
| Levy, R | 1 |
| Wolfe, F | 1 |
| Weisman, M | 1 |
| Zeng, Q | 1 |
| Morrison, B | 1 |
| Bolognese, J | 2 |
| Seidenberg, B | 2 |
| Gertz, BJ | 1 |
| Cannon, GW | 1 |
| Caldwell, JR | 1 |
| Holt, P | 1 |
| McLean, B | 1 |
| Ehrich, E | 1 |
| Mukhopadhyay, S | 1 |
| Daniels, B | 1 |
| Jawad, AS | 1 |
| Adler, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 trials available for rofecoxib and Osteoarthritis of Knee
| Article | Year |
|---|---|
A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparati | 2009 |
Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.
Topics: Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adminis | 2002 |
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; M | 2003 |
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase I | 2004 |
Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Computer Terminals; Female; Hip Joint; Humans; Knee J | 2004 |
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Butano | 2004 |
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response | 2005 |
Preemptive oral rofecoxib plus postoperative intraarticular bupivacaine for pain relief after arthroscopic knee surgery.
Topics: Administration, Oral; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Arthroscop | 2005 |
Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug | 2005 |
Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; beta-Endorphin; Biomarkers; Cycloo | 2006 |
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase 2 Inhibitor | 2006 |
An analgesic model for assessment of acute pain response in osteoarthritis of the knee.
Topics: Acute Disease; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Doub | 2006 |
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Double-Blind Method; Female; Humans; Lactones; Male; Midd | 2006 |
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibi | 1999 |
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double- | 2000 |
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; C | 2002 |
12 other studies available for rofecoxib and Osteoarthritis of Knee
| Article | Year |
|---|---|
Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2 Inhibitors; Di | 2016 |
Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients.
Topics: Administration, Oral; Aged; Ambulatory Care; Cyclooxygenase Inhibitors; Drug Administration Schedule | 2003 |
Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lactones; Male; Middle Aged; Osteoart | 2002 |
[Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills].
Topics: Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Formularies, Homeopathic as To | 2004 |
Vioxx curbs knee pain. But the competition, at higher doses, is no slouch when taken with stomach protecting medications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Osteoarthritis, Knee; Sulfones | 2004 |
Retroperitoneal hematoma following rofecoxib and enoxaparin coadministration in a patient with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Cyclooxygenase Inhibitors; Enoxaparin; Hemat | 2005 |
Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Calcitonin Gene-Related P | 2007 |
The patient's perspective on the recall of Vioxx.
Topics: Aged; Cardiovascular Diseases; Communication; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control | 2006 |
Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia.
Topics: Amines; Analgesics; Animals; Arthralgia; Cyclohexanecarboxylic Acids; Cyclooxygenase 2 Inhibitors; D | 2006 |
[Rofecoxib-induced psychosis].
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Female; Follow-Up Studies; Hallucinations; H | 2007 |
EULAR recommendations for the management of knee osteoarthritis.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis, Knee; Practice Guidelines as | 2001 |
Arthritis: what it is, why you get it and how to stop the pain.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy | 2001 |